Comorbidities may offset expected improved survival after transcatheter aortic valve replacement - Archive ouverte HAL Access content directly
Journal Articles European Heart Journal Open Year : 2022

Comorbidities may offset expected improved survival after transcatheter aortic valve replacement

Pierre Lantelme
Matthieu Aubry
Jacques Chan Peng
  • Function : Author
Benjamin Riche
  • Function : Author
Géraud Souteyrand
  • Function : Author
Philippe Jaafar
  • Function : Author
Brahim Harbaoui
Olivier Muller
Benoit Cosset
  • Function : Author
Mattia Pagnoni
  • Function : Author
Thibaut Manigold
  • Function : Author

Abstract

Abstract Aims After transcatheter aortic valve replacement (TAVR), cardiovascular and non-cardiovascular comorbidities may offset the survival benefit from the procedure. We aimed to describe the relationships between that benefit and patient comorbidities. Methods and results The study pooled two European cohorts of patients with severe aortic stenosis (AS-pooled): one with patients who underwent (cohort of AS patients treated by TAVR, N = 233) and another with patients who did not undergo TAVR (cohort of AS patients treated medically; N = 291). The investigators collected the following: calcification prognostic impact (CAPRI) and Charlson scores for cardiovascular and non-cardiovascular comorbidities, activities of daily living (ADL)/instrumental activities of daily living (IADL) scores for frailty as well as routine Society of Thoracic Surgeons (STS) score and Logistic Euroscore. Unlike ADL/IADL scores, CAPRI and Charlson scores were found to be independent predictors of 1-year all-cause death in the AS-pooled cohort, with and without adjustment for STS score or Logistic Euroscore; they were thus retained to define a three-level prognostic scale (good, intermediate, and poor). The survival benefit from TAVR—vs. no TAVR—was stratified according to these three prognosis categories. The beneficial effect of TAVR on 1-year all-cause death was significant in patients with good and intermediate prognosis, hazard ratio (95% confidence interval): 0.36 (0.18; 0.72) and 0.32 (0.15; 0.67). That effect was reduced and not statistically significant in patient with poor prognosis [0.65 (0.22; 1.88)]. Conclusion The study showed that, beyond a given comorbidity burden (as assessed by CAPRI and Charlson scores), the probability of death within a year was high and poorly reduced by TAVR. This indicates the futility of TAVR in patients in the poor prognosis category.

Dates and versions

hal-04176564 , version 1 (03-08-2023)

Identifiers

Cite

Pierre Lantelme, Matthieu Aubry, Jacques Chan Peng, Benjamin Riche, Géraud Souteyrand, et al.. Comorbidities may offset expected improved survival after transcatheter aortic valve replacement. European Heart Journal Open, 2022, 2 (3), ⟨10.1093/ehjopen/oeac029⟩. ⟨hal-04176564⟩

Collections

HCL
9 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More